直接口服抗凝药试验中肾功能谱系的血栓栓塞与出血结局
本研究基于RE-LY(n=18,049)、ARISTOTLE(n=18,187)和ENGAGE AF(n=20,798)三项随机试验,按基线GFR≥60、45-59、<45 mL/min/1.73 m2分层,比较DOAC与华法林使用者卒中/系统性栓塞、出血及复合终点的发生率。结果显示肾功能显著影响口服抗凝药的安全性与有效性,调整后华法林、达比加群和艾多沙班在GFR<60时出血风险升高,而阿哌沙班未见出血风险增加。
要点
- 肾功能下降与华法林、达比加群、艾多沙班出血风险升高相关
- 阿哌沙班在GFR 45-59及<45时未见出血风险增加
- 肾功能显著影响口服抗凝药的安全性与有效性
核心结论
- 肾功能显著影响口服抗凝药的安全性与有效性。
- 调整后华法林、达比加群和艾多沙班在GFR<60时出血风险升高,阿哌沙班未见增加。
研究设计与样本
- 基于RE-LY(n=18,049)、ARISTOTLE(n=18,187)和ENGAGE AF(n=20,798)三项随机试验的分析。
- 基线肾功能按GFR≥60(参照)、45-59、<45 mL/min/1.73 m2分层,比较各层事件发生率。
- 采用Cox回归、意向性治疗分析并调整已知预测因素估计风险比。
主要发现
- 25-29%参与者GFR 45-59,9.5-12.6%参与者GFR<45。
- 华法林使用者在GFR 45-59和<45时出血发生率高于GFR≥60(P<0.0001),ARISTOTLE和ENGAGE中卒中/SEE发生率亦更高(P≤0.05)。
- 达比加群使用者在GFR 45-59和<45时卒中/SEE(P≤0.02)、出血(P<0.001)及两项复合终点(P<0.0001)发生率更高。
- 阿哌沙班和艾多沙班使用者在GFR 45-59和<45时出血(P≤0.05)及复合终点(P≤0.05)发生率更高。
关键数值与推荐
- 调整后华法林使用者在ARISTOTLE和RE-LY中GFR<60时出血风险升高(P<0.05)。
- 调整后达比加群使用者出血风险升高(P<0.001),艾多沙班使用者出血风险升高(P≤0.005)。
- 调整后阿哌沙班使用者出血风险未增加(GFR 45-59 P=0.08;GFR<45 P=0.71)。
临床怎么用
- 临床选用DOAC时应结合基线肾功能评估出血与血栓栓塞风险。
- 肾功能下降患者使用华法林、达比加群或艾多沙班时需加强出血监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease is a common comorbidity among patients taking direct-acting oral anticoagulants (DOACs). Herein, we evaluate the influence of kidney function on stroke or systemic embolism (SEE), hemorrhage, and composite end points (stroke/SEE/hemorrhage/death and stroke/SEE/death) among patients on DOACs and warfarin. Baseline kidney function was categorized as glomerular filtration rate (GFR) ≥ 60 (reference), 45-59, and < 45mL/min/1.73 m2 for participants in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) (n = 18,049), Apixaban for Reduction in Stroke and Other Thromboembolic Events (ARISTOTLE) (n = 18,187), and The Effective Anticoagulation with Factor Xa Next Generation in AF (ENGAGE AF) (n = 20,798) trials. Incidence of events was compared across GFR categories. Hazard ratios for events were estimated using Cox regression using intention-to-treat analysis adjusting for known predictors. A large proportion of participants had GFR < 60 (25-29% had 45 ≤ GFR < 60 and 9.5-12.6% with GFR < 45). Compared with patients with GFR ≥ 60, warfarin users across the trials with GFR ≥ 45-59 and GFR < 45 had a higher incidence of hemorrhage (P values < 0.0001) and warfarin users in the ARISTOTLE and ENGAGE trials had higher incidence of stroke/SEE (P values ≤ 0.05). Compared with patients with GFR ≥ 60, dabigatran users with GFR ≥ 45-59 and GFR < 45 had a higher incidence of stroke/SEE (P ≤ 0.02), hemorrhage (P < 0.001), and both composite end points (P < 0.0001). Compared with patients with GFR ≥ 60, apixaban and edoxaban users with GFR ≥ 45-59 and GFR < 45 had a higher incidence of hemorrhage (P values ≤ 0.05) and composite end points (P values ≤ 0.05). After adjustment, compared with patients with GFR ≥ 60, warfarin users with GFR < 60 in the ARISTOTLE and RE-LY trials had a higher risk of hemorrhage (P < 0.05), as did dabigatran (P < 0.001) and edoxaban (P ≤ 0.005) users, while apixaban users did not exhibit an increased risk (P = 0.08 GFR ≥ 45-59; P = 0.71 GFR < 45). Kidney function significantly influences the safety and efficacy of oral anticoagulants.
引用
- Limdi NA, Beasley TM, Sun J, et al. Thromboembolic and Hemorrhagic Outcomes in the Direct Oral Anticoagulant Trials Across the Spectrum of Kidney Function. Clin Pharmacol Ther. 2021. PMID: 33278832. doi:10.1002/cpt.2131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。